Literature DB >> 1933970

Blood pressure and sleep apnea: results of long-term nasal continuous positive airway pressure therapy.

J Mayer1, H Becker, U Brandenburg, T Penzel, J H Peter, P von Wichert.   

Abstract

Arterial blood pressure patterns in 12 men with sleep apnea and arterial hypertension were studied at baseline and after 6 months' therapy with nasal continuous positive airway pressure (nCPAP). Preexisting antihypertensive medication was discontinued 1 week before baseline measurements. Weight did not change during the study period; body mass index was 29.3 (range, 25.4-38.5) vs. 29.3 (25.0-38.5). During therapy the apnea index decreased from 58 (range 30-73) to 2 (range 0-7) apneic episodes per hour (p less than 0.01). Intra-arterial systolic (BP sys.) and diastolic (BP dias.) blood pressure and heart rate decreased during therapy (p less than 0.001). Mean values +/- 95% confidence intervals were as follows: BP sys., 147.1 (+/- 1.6) mm Hg vs. 126.4 (+/- 1.5) mm Hg; BP dias., 81.6 (+/- 0.8) mm Hg vs. 69.4 (+/- 0.6) mm Hg; heart rate, 68.8 (+/- 0.7) beats/min vs. 65.4 (+/- 0.7) beats/min. Furthermore, the variability of these parameters decreased during therapy: variability BP sys., 53.8 (+/- 1.1) mm Hg vs. 25.6 (+/- 1.1) mm Hg; variability BP dias., 35.6 (+/- 0.7) mm Hg vs. 17.9 (+/- 0.7) mm Hg; variability of heart rate, 28.1 (+/- 0.7) beats/min vs. 14.9 (+/- 0.7) beats/min (p less than 0.001). During treatment we found that blood pressure scores already dropped during the awake phase, with a further decrease during non-REM and REM sleep (p less than 0.001). Our results, which demonstrate the reversibility of high blood pressure upon treatment of sleep apnea, indicate that sleep apnea can be an etiological factor in hypertension. Sleep apnea should therefore be considered in the differential diagnosis of arterial hypertension.

Entities:  

Mesh:

Year:  1991        PMID: 1933970     DOI: 10.1159/000174864

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  26 in total

Review 1.  Prognosis and sleep disordered breathing in heart failure.

Authors:  I Wilcox; S G McNamara; T Wessendorf; G N Willson; A J Piper; C E Sullivan
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

Review 2.  "Syndrome Z": the interaction of sleep apnoea, vascular risk factors and heart disease.

Authors:  I Wilcox; S G McNamara; F L Collins; R R Grunstein; C E Sullivan
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

Review 3.  CPAP therapy: outcomes and patient use.

Authors:  N J Douglas; H M Engleman
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

Review 4.  Sleep . 6: obstructive sleep apnoea/hypopnoea syndrome and hypertension.

Authors:  G V Robinson; J R Stradling; R J O Davies
Journal:  Thorax       Date:  2004-12       Impact factor: 9.139

Review 5.  Sleep.7: positive airway pressure therapy for obstructive sleep apnoea/hypopnoea syndrome.

Authors:  P Gordon; M H Sanders
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

Review 6.  Disorders of sleep: an overview.

Authors:  Leon Ting; Atul Malhotra
Journal:  Prim Care       Date:  2005-06       Impact factor: 2.907

7.  How best to determine optimal nasal CPAP in patients with OSAH?

Authors:  A Mulgrew; J A Fleetham
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

8.  Metabolic syndrome and sleep apnea.

Authors:  I Kostoglou-Athanassiou; P Athanassiou
Journal:  Hippokratia       Date:  2008-04       Impact factor: 0.471

9.  Variables affecting the change in systemic blood pressure in response to nasal CPAP in obstructive sleep apnea patients.

Authors:  Junaid Malik; Christopher L Drake; David W Hudgel
Journal:  Sleep Breath       Date:  2008-03       Impact factor: 2.816

10.  Non-invasive beat to beat arterial blood pressure during non-REM sleep in obstructive sleep apnoea and snoring.

Authors:  R J Davies; J Crosby; K Vardi-Visy; M Clarke; J R Stradling
Journal:  Thorax       Date:  1994-04       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.